Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease

Hadeel Khadawardi, Theodore K. Marras, Mahtab Mehrabi, Sarah K. Brode

Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019
Journal Issue: April
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Hadeel Khadawardi, Theodore K. Marras, Mahtab Mehrabi, Sarah K. Brode. Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease. Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019

Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease
Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Year: 2018



Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systemic review and meta-analysis
Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection
Year: 2019


Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Year: 2019




Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020


Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease
Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019
Year: 2019



The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 546s
Year: 2002

Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment
Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections
Year: 2009


Hospital-based antibiotic use in patients with Mycobacterium avium complex
Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018
Year: 2018



The clinical effect of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease - including a long-term follow-up study
Source: Eur Respir J 2004; 24: Suppl. 48, 721s
Year: 2004

The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study
Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019
Year: 2020



A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease
Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis
Year: 2006


Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015


Combined chemotherapy in Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 657s
Year: 2005

Effect of clarithromycin alone and clarithromycin containing regimen for mycobacteriun avium complex pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 558s
Year: 2006

Evaluation of the efficacy and safety of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis; a clinical trial
Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Year: 2008



Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial
Source: Eur Respir J 2002; 20: Suppl. 38, 546s
Year: 2002

The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease
Source: Eur Respir J 2015; 45: 1177-1179
Year: 2015


Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2005; 26: 1092-1096
Year: 2005